Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2020-10-16 12:22 pm Purchase | 2020-10-06 | 13D | Oncorus, Inc. ONCR | James E. Flynn | 2,848,970 13.040% | 2,848,970 (New Position) | Filing History |
| 2020-10-09 3:51 pm Purchase | 2020-09-29 | 13D | Graybug Vision, Inc. GRAY | James E. Flynn | 377,265 26.290% | 377,265 (New Position) | Filing History |
| 2020-10-09 3:29 pm Purchase | 2020-10-05 | 13G | Nuo Therapeutics, Inc. AURX | James E. Flynn | 2,700,000 9.240% | 2,700,000 (New Position) | Filing History |
| 2020-09-29 4:06 pm Purchase | 2020-09-18 | 13G | Metacrine, Inc. MTCR | James E. Flynn | 927,469 3.580% | 927,469 (New Position) | Filing History |
| 2020-09-21 4:41 pm Purchase | 2020-09-09 | 13D | HIGHCAPE CAP ACQUISITION CRP U CAPAU | James E. Flynn | 1,000,000 8.400% | 1,000,000 (New Position) | Filing History |
| 2020-08-20 4:17 pm Purchase | 2020-08-10 | 13D | Acutus Medical, Inc. AFIB | James E. Flynn | 4,775,916 17.140% | 4,775,916 (New Position) | Filing History |
| 2020-08-10 4:58 pm Purchase | 2020-07-31 | 13G | OraSure Technologies, Inc. OSUR | James E. Flynn | 3,471,600 4.850% | 3,471,600 (New Position) | Filing History |
| 2020-08-10 2:52 pm Purchase | 2020-08-07 | 13G | Puma Biotechnology, Inc. PBYI | James E. Flynn | 2,278,153 5.740% | 2,278,153 (New Position) | Filing History |
| 2020-08-06 10:58 am Purchase | 2020-07-28 | 13G | Inozyme Pharma, Inc. INZY | James E. Flynn | 1,150,299 5.150% | 1,150,299 (New Position) | Filing History |
| 2020-07-28 12:51 pm Purchase | 2020-07-28 | 13G | Annexon, Inc. ANNX | James E. Flynn | 1,617,828 4.490% | 1,617,828 (New Position) | Filing History |
| 2020-07-14 11:40 am Purchase | 2020-07-14 | 13G | Nkarta, Inc. NKTX | James E. Flynn | 2,419,872 7.950% | 2,419,872 (New Position) | Filing History |
| 2020-07-01 4:01 pm Sale | 2020-06-26 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 5,144,539 33.500% | -946,711 (-15.54%) | Filing History |
| 2020-07-01 1:52 pm Purchase | 2020-06-22 | 13G | IVERIC bio, Inc. ISEE | James E. Flynn | 5,767,409 6.820% | 5,767,409 (New Position) | Filing History |
| 2020-06-30 4:35 pm Sale | 2020-06-30 | 13G | Aerie Pharmaceuticals, Inc. AERI | James E. Flynn | 494,216 1.060% | -2,037,931 (-80.48%) | Filing History |
| 2020-06-25 5:22 pm Unchanged | 2020-06-24 | 13D | AdaptHealth Corp. AHCO | James E. Flynn | 19,674,202 4.900% | 0 (Unchanged) | Filing History |
| 2020-06-19 12:10 pm Purchase | 2020-06-19 | 13G | AVEO Pharmaceuticals, Inc. AVEO | James E. Flynn | 1,574,000 6.090% | 1,574,000 (New Position) | Filing History |
| 2020-06-16 2:11 pm Purchase | 2020-06-16 | 13G | Generation Bio Co. GBIO | James E. Flynn | 1,186,215 2.660% | 1,186,215 (New Position) | Filing History |
| 2020-06-08 5:10 pm Purchase | 2020-05-28 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 6,091,250 39.760% | 6,091,250 (New Position) | Filing History |
| 2020-05-26 5:09 pm Unchanged | 2020-05-21 | 13D | AdaptHealth Corp. AHCO | James E. Flynn | 19,674,202 37.860% | 0 (Unchanged) | Filing History |
| 2020-05-05 3:23 pm Unchanged | 2020-04-29 | 13D | AdaptHealth Corp. AHCO | James E. Flynn | 19,674,202 37.860% | 0 (Unchanged) | Filing History |